{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:25:50Z","timestamp":1788492350241,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clml.2024.06.004","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T17:24:54Z","timestamp":1719249894000},"page":"762-769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma"],"prefix":"10.1016","volume":"24","author":[{"given":"Tanvi H","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-8042","authenticated-orcid":false,"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2024.06.004_bib0001","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.06.004_bib0002","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.06.004_bib0003","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.soncn.2017.05.012","article-title":"Pathobiology and diagnosis of multiple myeloma","volume":"33","author":"Brigle","year":"2017","journal-title":"Semin Oncol Nurs"},{"issue":"5","key":"10.1016\/j.clml.2024.06.004_bib0004","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2024.06.004_bib0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2586","article-title":"Multiple myeloma: every year a new standard?","volume":"37","author":"Rajkumar","year":"2019","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.06.004_bib0006","first-page":"58","article-title":"Haematology: multiple myeloma","volume":"19","author":"Firth","year":"2019","journal-title":"Clin Med (Lond)"},{"issue":"8","key":"10.1016\/j.clml.2024.06.004_bib0007","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2024.06.004_bib0008","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/ejh.13840","article-title":"Treatment horizon in multiple myeloma","volume":"109","author":"Soekojo","year":"2022","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.06.004_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","article-title":"Treatment options for triple-class refractory multiple myeloma","volume":"20","author":"Mikhael","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.clml.2024.06.004_bib0010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/oncolo\/oyad306","article-title":"Perspectives on the treatment of multiple myeloma","volume":"29","author":"Rafae","year":"2024","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.clml.2024.06.004_bib0011","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/14740338.2023.2274420","article-title":"A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma","volume":"22","author":"Midha","year":"2023","journal-title":"Expert Opin Drug Saf"},{"issue":"4\u20136","key":"10.1016\/j.clml.2024.06.004_bib0012","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14789450.2022.2142564","article-title":"The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed\/refractory disease","volume":"19","author":"Richardson","year":"2022","journal-title":"Expert Rev Proteomics"},{"issue":"11","key":"10.1016\/j.clml.2024.06.004_bib0013","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.06.004_bib0014","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMe2307370","article-title":"Mezigdomide and Multiple Myeloma","volume":"14","author":"Shortt","year":"2023","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.clml.2024.06.004_bib0015","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.clml.2024.06.004_bib0016","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A cereblon modulator (CC-220) with improved degradation of ikaros and aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.clml.2024.06.004_bib0017","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40364-020-0182-y","article-title":"Novel immunomodulatory drugs and neo-substrates","volume":"8","author":"Gao","year":"2020","journal-title":"Biomark Res"},{"key":"10.1016\/j.clml.2024.06.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100994","article-title":"Targeting cereblon in hematologic malignancies","volume":"57","author":"Fuchs","year":"2023","journal-title":"Blood Rev"},{"issue":"11","key":"10.1016\/j.clml.2024.06.004_bib0019","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/2159-8290.CD-NB2023-0065","article-title":"Mezigdomide data show CELMoD potential","volume":"13","year":"2023","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.clml.2024.06.004_bib0020","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma","volume":"389","author":"Richardson","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2024.06.004_bib0021","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1182\/hematology.2022000335","article-title":"Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma","volume":"2022","author":"Holstein","year":"2022","journal-title":"Hematology"},{"issue":"9","key":"10.1016\/j.clml.2024.06.004_bib0022","doi-asserted-by":"crossref","first-page":"e5139","DOI":"10.1002\/bmc.5139","article-title":"Pharmacokinetics, bioavailability and metabolism of CC-92480 in rat by liquid chromatography combined with electrospray ionization tandem mass spectrometry","volume":"35","author":"You","year":"2021","journal-title":"Biomed Chromatogr"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2024.06.004_bib0023","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2019-124345","article-title":"CC-92480, a novel cereblon E3 ligase modulator, is synergistic with dexamethasone, bortezomib, and daratumumab in multiple myeloma","volume":"134","author":"Wong","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.06.004_bib0024","doi-asserted-by":"crossref","first-page":"e799","DOI":"10.1016\/S2352-3026(22)00322-2","article-title":"Iberdomide with dexamethasone: a new backbone for myeloma treatment?","volume":"9","author":"Rodriguez-Otero","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.06.004_bib0025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bcp.15498","article-title":"Model-based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma","volume":"89","author":"Cheng","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.clml.2024.06.004_bib0026","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.06.004_bib0027","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1182\/blood-2018-99-113383","article-title":"Iberdomide (CC-220) has synergistic anti-tumor and immunostimulatory activity against multiple myeloma in combination with both bortezomib and dexamethasone, or in combination with daratumumab in vitro","volume":"132","author":"Amatangelo","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.06.004_bib0028","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2023-174443","article-title":"Mezigdomide (MEZI) plus dexamethasone (DEX) and daratumumab (DARA) or elotuzumab (ELO) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial","volume":"142","author":"Richardson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.06.004_bib0029","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S2152-2650(21)02087-5","article-title":"OAB-013: iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"21","author":"Lonial","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.06.004_bib0030","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2023-177564","article-title":"Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed MM: first results of the phase 2 EMN26 study","volume":"142","author":"van de Donk","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.06.004_bib0031","unstructured":"Pullen L.C. Phase II study results: iberdomide effective as maintenance after autologous transplant. 2023; Accessed May 1, 2024. https:\/\/ashpublications.org\/ashclinicalnews\/News\/7631\/Phase-II-Study-Results-Iberdomide-Effective-as"},{"key":"10.1016\/j.clml.2024.06.004_bib0032","unstructured":"Mezigdomide (CC-92480) post idecabtagene vicleucel in treating patients with relapsed multiple myeloma. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT06048250."},{"key":"10.1016\/j.clml.2024.06.004_bib0033","unstructured":"Iberdomide versus observation off therapy after idecabtagene vicleucel CAR-T for multiple myeloma. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT06179888."},{"key":"10.1016\/j.clml.2024.06.004_bib0034","unstructured":"A study to evaluate mezigdomide, bortezomib and dexamethasone (MEZIVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM). Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT05519085."},{"key":"10.1016\/j.clml.2024.06.004_bib0035","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/S2152-2650(23)01446-5","article-title":"MM-372 a phase III, two-stage, randomized study of mezigdomide, bortezomib, and dexamethasone (MeziVd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed\/refractory multiple myeloma (RRMM): SUCCESSOR-1","volume":"23","author":"Richardson","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.06.004_bib0036","unstructured":"A study to evaluate mezigdomide in combination with carfilzomib and dexamethasone (MeziKD) versus carfilzomib and dexamethasone (Kd) in participants with relapsed or refractory multiple myeloma (SUCCESSOR-2). Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT05552976."},{"key":"10.1016\/j.clml.2024.06.004_bib0037","doi-asserted-by":"crossref","first-page":"S426","DOI":"10.1016\/j.htct.2023.09.801","article-title":"A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MEZIKD) versus carfilzomib And dexamethasone (KD) in relapsed\/refractory multiple myeloma (RRMM): successor-2","volume":"45","author":"Md","year":"2023","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.clml.2024.06.004_bib0038","unstructured":"Mezigdomide plus ixazomib and dexamethasone for relapsed and refractory multiple myeloma. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT06050512."},{"key":"10.1016\/j.clml.2024.06.004_bib0039","unstructured":"A study to evaluate alnuctamab in combination with mezigdomide in participants with relapsed and\/or refractory multiple myeloma. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT06163898."},{"key":"10.1016\/j.clml.2024.06.004_bib0040","unstructured":"Elotuzumab, CC-92480, and dexamethasone for the treatment of relapsed or refractory myeloma after cd38- and bcma-targeted therapies. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT05981209."},{"key":"10.1016\/j.clml.2024.06.004_bib0041","unstructured":"A study to evaluate safety, drug levels and effectiveness of CC-92480 (BMS-986348) in combination with other treatments in participants with relapsed or refractory multiple myeloma. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT05372354."},{"key":"10.1016\/j.clml.2024.06.004_bib0042","unstructured":"A study to evaluate the safety, effectiveness and tolerable dose of BMS-986393 in novel combinations in participants with relapsed and\/or refractory multiple myeloma. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT06121843."},{"key":"10.1016\/j.clml.2024.06.004_bib0043","unstructured":"Iberdomide-dexamethasone alone or in combination with standard MM treatment regimens in transplant ineligible newly diagnosed patients. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT05527340."},{"key":"10.1016\/j.clml.2024.06.004_bib0044","unstructured":"Study of iberdomide, bortezomib, and dexamethasone for ND-NTE MM patients. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT05272826."},{"key":"10.1016\/j.clml.2024.06.004_bib0045","unstructured":"Carfilzomib, iberdomide (CC-220) and dexamethasone (KID) in transplant eligible multiple myeloma. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT05199311."},{"key":"10.1016\/j.clml.2024.06.004_bib0046","unstructured":"Iberdomide, daratumumab, bortezomib, and dexamethasone for treatment of newly diagnosed multiple myeloma, IDEAL study. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT05392946."},{"key":"10.1016\/j.clml.2024.06.004_bib0047","unstructured":"Iberdomide alone or in combination with dexamethasone for the treatment of intermediate- or high-risk smoldering multiple myeloma. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT04776395."},{"key":"10.1016\/j.clml.2024.06.004_bib0048","unstructured":"A study to compare iberdomide maintenance versus lenalidomide maintenance therapy following autologous stem cell transplant in participants with newly diagnosed multiple myeloma. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT05827016."},{"key":"10.1016\/j.clml.2024.06.004_bib0049","unstructured":"Iberdomide maintenance therapy in patients with multiple myeloma. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT05177536."},{"key":"10.1016\/j.clml.2024.06.004_bib0050","unstructured":"Study of iberdomide in people with multiple myeloma who have had an autologous hematopoietic stem cell transplant (AHCT). Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT05354557."},{"key":"10.1016\/j.clml.2024.06.004_bib0051","unstructured":"Combination regimens in MM Post AHCT to eliminate MRD utilizing iberdomide. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT05434689."},{"key":"10.1016\/j.clml.2024.06.004_bib0052","unstructured":"Iberdomide and daratumumab as maintenance therapy after an autologous stem cell transplant for multiple myeloma. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT06107738."},{"key":"10.1016\/j.clml.2024.06.004_bib0053","unstructured":"A study evaluating the safety and efficacy of multiple treatments in participants with multiple myeloma. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT05583617."},{"key":"10.1016\/j.clml.2024.06.004_bib0054","unstructured":"Open-label study comparing iberdomide, daratumumab and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM). Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT04975997."},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.06.004_bib0055","doi-asserted-by":"crossref","first-page":"TPS8069","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8069","article-title":"EXCALIBER-RRMM: a phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Lonial","year":"2023","journal-title":"J Clin Onco"},{"key":"10.1016\/j.clml.2024.06.004_bib0056","unstructured":"Study of novel regimens in relapsed or refractory multiple myeloma. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT05289492."},{"key":"10.1016\/j.clml.2024.06.004_bib0057","unstructured":"A study of iberdomide (CC-220) in combination with elotuzumab and dexamethasone for relapsed\/refractory multiple myeloma. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT05560399."},{"key":"10.1016\/j.clml.2024.06.004_bib0058","unstructured":"Iberdomide combined with low-dose cyclophosphamide and dexamethasone. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT04392037."},{"key":"10.1016\/j.clml.2024.06.004_bib0059","unstructured":"A multi-center open-label phase 2 study of ixazomib, iberdomide and dexamethasone in elderly patients with multiple myeloma at first relapse.\". Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT04998786."},{"key":"10.1016\/j.clml.2024.06.004_bib0060","unstructured":"Iberdomide, daratumumab, carfilzomib, and dexamethasone (Iber-KDd) in patients with relapsed\/refractory multiple myeloma. Accessed May 1, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT05896228."},{"key":"10.1016\/j.clml.2024.06.004_bib0061","doi-asserted-by":"crossref","first-page":"e20043","DOI":"10.1200\/JCO.2023.41.16_suppl.e20043","article-title":"A phase I\/II study of carfilzomib, iberdomide (CC-220), and dexamethasone (KID) in patients with newly diagnosed transplant-eligible multiple myeloma","volume":"41","author":"Biran","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.clml.2024.06.004_bib0062","series-title":"Presented at: 2023 International Myeloma Society Annual Meeting","article-title":"Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible newly diagnosed multiple myeloma: results from the CC-220-MM-001 trial","author":"White","year":"2023"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T11:09:45Z","timestamp":1729595385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":62,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2152265024002386"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.06.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}